Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.10. | NICE recommends Santen's Roclanda to treat glaucoma and ocular hypertension | 10 | PharmaTimes | ||
06.08. | Santen and Cloudbreak enter licence agreement for pterygium treatment | 2 | Pharmaceutical Business Review | ||
06.08. | Santen Pharmaceutical Co., Ltd. GAAP EPS of Yen 27.85, revenue of Yen 72.34B | 1 | Seeking Alpha | ||
09.05. | Santen Pharmaceutical Co., Ltd. reports FY results | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVARTIS | 101,05 | 0,00 % | Es grünt so grün: NOVARTIS | Der Schweizer Pharmakonzern hat gestern positive Studienergebnisse für eine äußerst seltene Nierenkrankheit vorgelegt. Und er hat die Zulassungsanträge dafür in der EU, China und Japan abgeschlossen... ► Artikel lesen | |
MPH HEALTH CARE | 23,800 | 0,00 % | MPH Health Care Aktie: Solide Entwicklung im Gesundheitssektor | Die MPH Health Care AG verzeichnet eine positive Entwicklung im Gesundheitsmarkt. Der Aktienkurs liegt aktuell bei 24,60 EUR und konnte im vergangenen Monat um 4,68% zulegen. Besonders bemerkenswert... ► Artikel lesen | |
HIGH TIDE | 2,650 | +0,19 % | Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures | ||
COMPASS PATHWAYS | 4,400 | -0,90 % | Compass Pathways plc: Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates | Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point... ► Artikel lesen | |
PHARMASGP | 24,600 | 0,00 % | PharmaSGP Holding Aktie: Starke Kursentwicklung und hohe Dividendenrendite | ||
SHANGHAI FOSUN PHARMACEUTICAL | 1,732 | -0,97 % | Fosun Pharma Announces 2024Q3 Financial Results | Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion
Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer
... ► Artikel lesen | |
SEELOS THERAPEUTICS | 2,000 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 24.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.10.2024ISIN NameAU0000114977 BOOKTOPIA... ► Artikel lesen | |
LEANLIFE HEALTH | 0,010 | 0,00 % | CSE Bulletin: Delist - LeanLife Health Inc. (LLP) | Toronto, Ontario--(Newsfile Corp. - Le 19 juin/June 2024) - The common shares of LeanLife Health Inc. will be delisted from the CSE at market close today, June 19, 2024. LeanLife Health Inc.... ► Artikel lesen | |
PROMINO NUTRITIONAL SCIENCES | 0,035 | -23,33 % | Promino Nutritional Sciences Inc (2): Promino adds Netrition as Rejuvenate on-line retailer | ||
SAVARA | 3,260 | -1,81 % | Savara Inc.: Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 | Company-Sponsored Industry Symposium To Be Held at the ERS Congress Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases,... ► Artikel lesen | |
EVOLUS | 15,400 | -0,65 % | Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation | Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification... ► Artikel lesen | |
ATYR PHARMA | 2,820 | 0,00 % | aTyr Pharma stock soars to 52-week high, hits $3.6 | ||
CIPHER PHARMACEUTICALS | 9,800 | -0,51 % | Cipher Pharma earns price target raise at Stifel | ||
EVOKE PHARMA | 3,840 | 0,00 % | Evoke Pharma, Inc.: Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI | Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in... ► Artikel lesen | |
IMMUNOPRECISE ANTIBODIES | 0,406 | +6,28 % | ImmunoPrecise Pummeled Despite Advancing Anti-Aging Research with Mayo |